Diurnal mouthpiece ventilation and nocturnal non-invasive ventilation versus tracheostomy invasive ventilation in patients with amyotrophic lateral sclerosis.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Mar 2020
Historique:
pubmed: 31 5 2019
medline: 29 12 2020
entrez: 1 6 2019
Statut: ppublish

Résumé

Respiratory disorders are a major cause of morbidity and mortality in amyotrophic lateral sclerosis (ALS). Current guidelines suggest the provision of noninvasive ventilation (NIV) for symptomatic hypoventilation in patients with ALS. Inspite of these results the proportion of ALS patients on tracheostomy invasive ventilation (TIV) is relatively high. Thirty-two patients were included in the study: 16 patients were treated with nocturnal NIV associated with diurnal mouthpiece ventilation (MPV) and 16 with TIV .The primary endpoint of the study was to evaluate survival in the two groups. Secondary endpoints were to evaluate differences in the two populations in terms of clinical outcomes and quality of life (HRQoL). Cox analysis survival data shows no statically difference in the hazard function of the two groups. The comparison between the two groups showed a significant improvement in the average value of gas indices (paO2, paCO2) in the group treated with TIV in comparison to the group treated with MPV/NIV. Conversely, the evaluation of the questionnaires on HRQoL showed a higher score in patients treated with MPV/NIV compared to those treated with TIV. Ventilatory treatment with MPV and TIV did not demonstrate significant differences in survival. Patients treated with MPV reported a better HRQoL, although TIV group showed higher ventilatory parameters improvement than MPV group.

Sections du résumé

BACKGROUND BACKGROUND
Respiratory disorders are a major cause of morbidity and mortality in amyotrophic lateral sclerosis (ALS). Current guidelines suggest the provision of noninvasive ventilation (NIV) for symptomatic hypoventilation in patients with ALS. Inspite of these results the proportion of ALS patients on tracheostomy invasive ventilation (TIV) is relatively high.
METHODS METHODS
Thirty-two patients were included in the study: 16 patients were treated with nocturnal NIV associated with diurnal mouthpiece ventilation (MPV) and 16 with TIV .The primary endpoint of the study was to evaluate survival in the two groups. Secondary endpoints were to evaluate differences in the two populations in terms of clinical outcomes and quality of life (HRQoL).
RESULTS RESULTS
Cox analysis survival data shows no statically difference in the hazard function of the two groups. The comparison between the two groups showed a significant improvement in the average value of gas indices (paO2, paCO2) in the group treated with TIV in comparison to the group treated with MPV/NIV. Conversely, the evaluation of the questionnaires on HRQoL showed a higher score in patients treated with MPV/NIV compared to those treated with TIV.
CONCLUSIONS CONCLUSIONS
Ventilatory treatment with MPV and TIV did not demonstrate significant differences in survival. Patients treated with MPV reported a better HRQoL, although TIV group showed higher ventilatory parameters improvement than MPV group.

Identifiants

pubmed: 31146513
pii: S0031-0808.19.03644-9
doi: 10.23736/S0031-0808.19.03644-9
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-25

Auteurs

Antonello Nicolini (A)

Unit of Respiratory Diseases, General Hospital, Sestri Levante, Genoa, Italy - antonellonicolini@gmail.com.

Laura Parrinello (L)

Unit of Physical Medicine and Rehabilitation, General Hospital, Sestri Levante, Genoa, Italy.

Bruna Grecchi (B)

Unit of Physical Medicine and Rehabilitation, General Hospital, Sestri Levante, Genoa, Italy.

Fulvio Braido (F)

Clinic of Respiratory Diseases and Allergy, Department of Internal Medicine, San Martino University Hospital IRCCS, University of Genoa, Genoa, Italy.

Ilaria Baiardini (I)

Clinic of Respiratory Diseases and Allergy, Department of Internal Medicine, San Martino University Hospital IRCCS, University of Genoa, Genoa, Italy.

Corrado Ghirotti (C)

Clinic of Respiratory Diseases and Allergy, Department of Internal Medicine, San Martino University Hospital IRCCS, University of Genoa, Genoa, Italy.

Paolo Banfi (P)

Unit of Pulmonary Rehabilitation, Don Gnocchi Foundation IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH